Bevacizumab in ovarian cancer

Focus on clinical data and future perspectives

Research output: Contribution to journalArticle

Abstract

The past five years have yielded substantial developments in the management of advanced ovarian cancer. Initial promise shown by anti-angiogenic agents has translated into positive phase III trials in the front-line and recurrent settings. Nevertheless, several questions remain unanswered, including the most appropriate timing for initiation of anti-angiogenic therapy and patient selection for the various treatment approaches. This review article summarises the key results (including final overall survival data), from five pivotal phase III trials of bevacizumab, highlights emerging data with new maintenance strategies and considers unanswered questions and ongoing research to address uncertainties in treatment duration, re-exposure to bevacizumab in bevacizumab-pretreated patients and the potential integration of anti-angiogenic therapy into neoadjuvant treatment regimens.

Original languageEnglish
Pages (from-to)335-348
Number of pages14
JournalCritical Reviews in Oncology/Hematology
Volume97
DOIs
Publication statusPublished - Jan 1 2016

Fingerprint

Ovarian Neoplasms
Patient Selection
Neoadjuvant Therapy
Uncertainty
Therapeutics
Maintenance
Survival
Research
Bevacizumab

Keywords

  • Anti-angiogenic
  • Bevacizumab
  • Front-line
  • Ovarian cancer
  • Phase III
  • Vascular endothelial growth factor

ASJC Scopus subject areas

  • Oncology
  • Hematology
  • Geriatrics and Gerontology

Cite this

@article{488ac04eb4a449c6be4556b5f9c19f47,
title = "Bevacizumab in ovarian cancer: Focus on clinical data and future perspectives",
abstract = "The past five years have yielded substantial developments in the management of advanced ovarian cancer. Initial promise shown by anti-angiogenic agents has translated into positive phase III trials in the front-line and recurrent settings. Nevertheless, several questions remain unanswered, including the most appropriate timing for initiation of anti-angiogenic therapy and patient selection for the various treatment approaches. This review article summarises the key results (including final overall survival data), from five pivotal phase III trials of bevacizumab, highlights emerging data with new maintenance strategies and considers unanswered questions and ongoing research to address uncertainties in treatment duration, re-exposure to bevacizumab in bevacizumab-pretreated patients and the potential integration of anti-angiogenic therapy into neoadjuvant treatment regimens.",
keywords = "Anti-angiogenic, Bevacizumab, Front-line, Ovarian cancer, Phase III, Vascular endothelial growth factor",
author = "Nicoletta Colombo and Pierfranco Conte and Sandro Pignata and Francesco Raspagliesi and Giovanni Scambia",
year = "2016",
month = "1",
day = "1",
doi = "10.1016/j.critrevonc.2015.08.017",
language = "English",
volume = "97",
pages = "335--348",
journal = "Critical Reviews in Oncology/Hematology",
issn = "1040-8428",
publisher = "Elsevier Ireland Ltd",

}

TY - JOUR

T1 - Bevacizumab in ovarian cancer

T2 - Focus on clinical data and future perspectives

AU - Colombo, Nicoletta

AU - Conte, Pierfranco

AU - Pignata, Sandro

AU - Raspagliesi, Francesco

AU - Scambia, Giovanni

PY - 2016/1/1

Y1 - 2016/1/1

N2 - The past five years have yielded substantial developments in the management of advanced ovarian cancer. Initial promise shown by anti-angiogenic agents has translated into positive phase III trials in the front-line and recurrent settings. Nevertheless, several questions remain unanswered, including the most appropriate timing for initiation of anti-angiogenic therapy and patient selection for the various treatment approaches. This review article summarises the key results (including final overall survival data), from five pivotal phase III trials of bevacizumab, highlights emerging data with new maintenance strategies and considers unanswered questions and ongoing research to address uncertainties in treatment duration, re-exposure to bevacizumab in bevacizumab-pretreated patients and the potential integration of anti-angiogenic therapy into neoadjuvant treatment regimens.

AB - The past five years have yielded substantial developments in the management of advanced ovarian cancer. Initial promise shown by anti-angiogenic agents has translated into positive phase III trials in the front-line and recurrent settings. Nevertheless, several questions remain unanswered, including the most appropriate timing for initiation of anti-angiogenic therapy and patient selection for the various treatment approaches. This review article summarises the key results (including final overall survival data), from five pivotal phase III trials of bevacizumab, highlights emerging data with new maintenance strategies and considers unanswered questions and ongoing research to address uncertainties in treatment duration, re-exposure to bevacizumab in bevacizumab-pretreated patients and the potential integration of anti-angiogenic therapy into neoadjuvant treatment regimens.

KW - Anti-angiogenic

KW - Bevacizumab

KW - Front-line

KW - Ovarian cancer

KW - Phase III

KW - Vascular endothelial growth factor

UR - http://www.scopus.com/inward/record.url?scp=84952638192&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84952638192&partnerID=8YFLogxK

U2 - 10.1016/j.critrevonc.2015.08.017

DO - 10.1016/j.critrevonc.2015.08.017

M3 - Article

VL - 97

SP - 335

EP - 348

JO - Critical Reviews in Oncology/Hematology

JF - Critical Reviews in Oncology/Hematology

SN - 1040-8428

ER -